Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities

Ian Tracy, William Tapper, Anton Parker, Anne Gardiner, Shalal Sadullah, Guy Pratt, Adrian Copplestone, David Oscier, Oliver Giles Best

Research output: Contribution to journalLetterpeer-review

2 Citations (Scopus)

Abstract

Deletions and/or mutations of TP53 are associated with poor prognosis in patients with chronic lymphocytic leukaemia (CLL), even when these abnormalities are not present in the predominant clonal population (Rossi et al, 2014). Dysfunction of the TP53-CDKN1A (p21) pathway correlates strongly with TP53 structural abnormalities (Carter et al, 2004; Best et al, 2008), however 9·5% of unselected CLL cases have been reported to have an impaired CDKN1A response to DNA damage despite normal TP53 upregulation, termed Type C dysfunction (Johnson et al, 2009)...
Original languageEnglish
Pages (from-to)824-826
Number of pages3
JournalBritish Journal of Haematology
Volume178
Issue number5
DOIs
Publication statusPublished - Sep 2017
Externally publishedYes

Keywords

  • Alleles Cyclin-Dependent Kinase Inhibitor p21/*genetics/*metabolism *DNA Damage Gene Expression Genotype Humans Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/*genetics/*metabolism *Polymorphism, Genetic Polymorphism, Single Nucleotide *Signal Transduction Tumor Suppressor Protein p53/*genetics/*metabolism * tp53 *cell signalling *chronic lymphocytic leukaemia
  • chronic lymphocytic leukaemia
  • cell signalling
  • TP53

Fingerprint

Dive into the research topics of 'Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities'. Together they form a unique fingerprint.

Cite this